Bluebird bio — EHA 2017
40 slides from Bluebird bio's conference presentation, Jun 23, 2017
Slide 1: EHA 2017
EHA 2017 June 23, 2017 NASDAQ: BLUE Exhibit 99.1
Slide 2: Forward Looking Statements
These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre
Slide 3: Our Vision: Make Hope a Reality
Our Vision: Make Hope a Reality TRUE BLUE BLUE MOJO OUR PATIENTS OUR PEOPLE
Slide 4: Our Strategic Intent
Our Strategic Intent Severe Genetic Diseases Hematopoietic Stem Cells (HSCs) Immunotherapy T Cells Late Stage (LentiGlobin, Lenti-D) Big Near Term Opportunities (SCD, Multiple Myeloma) Best Team (350+) Great Partners Truly Integrated Platform Transformative Product Focus “Tetris” R&D (Anti-Pure Play
Slide 5: The Gene Therapy Product Company
T H E G E N E T H E R A P Y P R O D U C T C O M P A N Y Products on the Market Programs Nearing Commercialization Additional Programs in the Clinic 2+ 4+ 2+ Patient Impact ∞ World-class Gene Therapy Platform and Integrated Global Capabilities
Slide 6: How Do We Get There? Data, Execution and Development in 2017
How Do We Get There? Data, Execution and Development in 2017 LentiGlobin, TDT and SCD Update @ ASH LentiGlobin, TDT Update @ EHA CRB-401 Study Data (bb2121) @ ASCO DATA EXECUTION Initiate HGB-212 Study of LentiGlobin Confirm LentiD, CALD Clinical/ Regulatory Path Preparations for TDT EU MAA Filing F
Slide 7: CRB-401: All bb2121 Patients in Active Dose Cohorts Achieved an Objective Response
CRB-401: All bb2121 Patients in Active Dose Cohorts Achieved an Objective Response, Duration up to 54 Weeks * High tumor burden (>50% bone marrow involvement) Includes unscheduled assessments. bb2121 has induced durable and deepening responses in a heavily pre-treated population (median 7 prior ther
Slide 8: LentiGlobin Clinical Studies
LentiGlobin Clinical Studies NORTHSTAR (HGB-204) Phase 1/2 single-center study; all genotypes NORTHSTAR-3 (HGB-212) Phase 1/2 multicenter study; all genotypes HGB-205 (TDT and SCD) All 18 patients treated, with ≥ 6 months follow-up 2 patients have completed 2-year analysis HGB-206 (Severe SCD) 4 TDT
Slide 9: Key Questions
Key Questions Transfusion-Dependent β-thalassemia (TDT): Northstar-2 and HGB-205 With our new manufacturing process in Northstar-2, are we able to consistently manufacture drug product (DP) with higher vector copy number (VCN) and proportion of transduced cells? How do the early results from Northst
Slide 10: Phase 3 Study of LentiGlobin for TDT: Northstar-2 (HGB-207) Trial
A Phase 3 Study to Evaluate Safety and Efficacy of LentiGlobin Gene Therapy for Transfusion-Dependent β-thalassemia in Patients with non-β0/β0 Genotypes: The Northstar-2 (HGB-207) Trial Mark C. Walters, Alexis Thompson, Suradej Hongeng, Janet L. Kwiatkowski, Franco Locatelli, John Porter, Martin Sau
Slide 11: Gene Therapy for Transfusion-Dependent β-thalassemia (TDT)
Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) Autologous gene therapy aims to correct TDT without the immunologic risks of allogeneic HSCT In Northstar (HGB-204) and HGB-205 phase 1/2 studies LentiGlobin BB305 gene therapy has eliminated transfusions in most patients with non-β0/β0 geno
Slide 12: Northstar-2 (HGB-207) Study of LentiGlobin BB305 Gene Therapy
Northstar-2 (HGB-207) Study of LentiGlobin BB305 Gene Therapy Investigating efficacy and safety of LentiGlobin BB305 in adolescents and adults with TDT and non-β0/β0 genotypes Uses refined manufacturing process to yield higher DP VCNs Primary endpoint: proportion of patients who achieve “transfusion
Slide 13: Current Status of Northstar-2 Study
Current Status of Northstar-2 Study Consented N=16 Ineligible N=4* Stem Cell Mobilization complete N=6 Drug Product Manufacturing and Release Complete N=6 LentiGlobin Drug Product Infused N=3 (adult) First patient infused December 2016 Target: 15 treated patients (including ≥5 aged 12-17 years) Key
Slide 14: Overview of the Northstar-2 Study Process
Overview of the Northstar-2 Study Process Patient Treatment Centralized Manufacturing Pre-infusion Conditioning Stem Cell Collection Transduced Stem Cells Infused Select CD34+ cells + Cryopreserve, test and release DP 2 years follow-up Extension study (13 years) Up to 15 years total follow-up Immune
Slide 15: Northstar-2 Patient Characteristics
Northstar-2 Patient Characteristics N=3 treated patients to date Patient 1 2 3 Age (years) 20 20 22 Gender F F F Genotype β0/βE β0/βE IVS-I-5 (G>C) Pre-Treatment pRBC Transfusions (mL/kg/year)1 162.5 192.9 158.7 Liver Iron Concentration (mg/g) (normal range <1.1 mg/g) 18.8 19.6 1.4 Cardiac T2* (msec
Slide 16: Initial Safety Summary & Treatment-related Parameters
Initial Safety Summary & Treatment-related Parameters N=3 treated patients Patient 1 2 3 VCN in Drug Product1 2.9 2.4 3.2, 2.4 Vector positive cells 77% 53% 77%, 82% CD34+ Cell Dose (x106/kg) 7.0 13.6 8.1 Busulfan AUC (μM*min)2 4286 4337 4562 Neutrophil engraftment, study day3 25 24 19 Platelet engr
Slide 17: Improved Manufacturing Process Yields Higher Drug Product Vector Copy Number
Improved Manufacturing Process Yields Higher Drug Product Vector Copy Number and Proportion of Transduced Cells Vector copy number (VCN) in drug product Proportion of CD34+ cells transduced median 0.7 median 3.0 median 32% median 77% DP VCN for initial 6 subjects manufactured in Northstar-2 consiste
Slide 18: First Patient Treated in Northstar-2 Has Achieved Normal Total Hemoglobin
First Patient Treated in Northstar-2 with 6 Months Follow-up has Achieved Normal Total Hemoglobin After Discontinuing Transfusions 13.3 Last RBC transfusion: Day 33 4.8 7.1 9.5 HbAT87Q HbF HbA2 HbA HbE 4.2 2.2 1.1 Medians in non-β0/β0 genotypes (N=10) (data as of Sept 2016) 9.7 * N=6 patients in Nor
Slide 19: HbAT87Q in Northstar-2 Patients Match or Exceed Northstar
VCN over time Patient 1 Patient 2 Patient 3 Northstar (non-β0/β0 patients only*) HbAT87Q levels over time HbAT87Q in Patients Treated in Northstar-2 Match or Exceed HbAT87Q in Patients Achieving Early Transfusion Independence in Northstar DP lots for patients pending transplant Transfusion independe
Slide 20: Northstar-2 Patient 2: Phenotypic Profile of CD34+ Cells is Atypical
5 4 3 2 1 0 Dose of Indicated Population (x 106 cells/kg) Transduced Primitive Stem Cell Population Northstar-2 Patient 2: Phenotypic Profile of CD34+ Cells is Atypical Disproportionate number of lymphoid cells results in lower proportion of primitive stem cells available for transduction With the i
Slide 21: Summary and Next Steps
Summary and Next Steps The improved manufacturing process in Northstar-2 consistently yields higher DP VCNs and proportions of cells transduced Initial results show that the 3 patients treated to date have achieved in vivo VCN and HbAT87Q production as good or better than patients achieving transfus
Slide 22: HGB-205: Transfusion-Dependent Thalassemia (TDT)
HGB-205: Transfusion-Dependent Thalassemia (TDT)
Slide 23: HGB-205: Study Status
HGB-205: Study Status Patients consented & enrolled N=8 Cell collection and drug product manufacture complete N=7 Conditioning and drug product infusion complete N=7 Ineligible N=1 Follow-up after drug-product infusion for 7 treated patients (4 TDT, 3 SCD) Median: 23.4 months range: 3.4 – 42.2 month
Slide 24: HGB-205 TDT: Patient and Drug Product Characteristics and Safety
HGB-205 TDT: Patient and Drug Product Characteristics and Safety 1201 1202 1203 1206 Age at Enrollment (yrs) 18 16 19 17 Genotype β0/βE β0/βE homozygous IVS1 nt 110 G>A β0/βE Pre-Treatment pRBC Transfusions (mL/kg/yr)1 139 188 176 189 VCN in Drug Product2 1.5 2.1 0.8 1.1 CD34+ Cell Dose (x106/kg) 8.
Slide 25: HGB-205 TDT: Stable Peripheral VCN and Durable HbAT87Q Production
HGB-205 TDT: Stable Peripheral VCN Over Time and Durable HbAT87Q Production VCN over Time HbAT87Q Levels over Time
Slide 26: HGB-205 TDT: Consistent and Durable Transfusion Independence Up to 3.5 Years
HGB-205 TDT: Consistent and Durable Transfusion Independence Up to 3.5 Years 11.3 8.3 12.9 11.4 Total Hb* *Hemoglobin (g/dL) at most recent study visit + Discontinued iron chelation and transitioned to therapeutic phlebotomy: Patients 1201 (started Aug. 2016), 1202 (started Nov. 2015), 1206 (started
Slide 27: HGB-205: Sickle Cell Disease (SCD)
HGB-205: Sickle Cell Disease (SCD)
Slide 28: ASH 2016: 8% to 48% Anti-Sickling Hemoglobin at Last Follow Up
ASH 2016: 8% to 48% Anti-Sickling Hemoglobin at Last Follow Up 12 12 9 9 6 6 9 48% Anti-Sickling Hb 30.0% 14.2% 18.3% 22.8% 16.5% 7.9% 21 18.7% 1301 1303 1304 1306 1308 1309 1310 1204 12 12 9 9 6 9 6 21 Follow up (Months) Data as of Sept 9, 2016 [HGB-205] and Nov 9, 2016 [HGB-206]
Slide 29: ASH 2016: Vector Copy Number in Drug Product and Peripheral Blood
ASH 2016: Vector Copy Number (VCN) in Drug Product and Peripheral Blood Vector copy number (VCN; per diploid genome) VCN drop from drug product to peripheral blood in HGB-206 Peripheral blood VCN over time 1204 Data as of Sept 9, 2016 [HGB-205] and Nov 9, 2016 [HGB-206]
Slide 30: Protocol and Process Changes to Potentially Improve Outcomes in SCD Patients
Protocol and Process Changes to Potentially Improve Outcomes in SCD Patients Hypoxic, inflamed marrow Pre-harvest transfusions to reduce marrow inflammation, hypoxia Low yield harvest Additional changes to manufacturing process to increase cell dose Poor transduction New manufacturing process Inadeq
Slide 31: HGB-205 SCD: Patient and Drug Product Characteristics
HGB-205 SCD: Patient and Drug Product Characteristics 1204 1207 1208 Age at Enrollment (yrs) 13 16 21 Genotype βS/βS βS/βS βS/β0 Busulfan AUC (average, μM*min) 4,841 5,022 5,447 CD34+ Cell Dose (x106/kg) 5.6 4.7 3.0 VCN in Drug Product1 1.0/1.2 0.7/1.0 0.8/0.5 Follow-up (months) 31.7 6.1 3.4 Neutrop
Slide 32: HGB-205 SCD: Durable Effect in Patient 1204
HGB-205 SCD: Durable Effect in Patient 1204 Total Hb 12.4 g/dL VCN 2.3 HbA (transfused) HbS 48% HbA2 2% HbF <1% HbAT87Q 50%
Slide 33: HGB-205 SCD: Safety and Clinical Status in Severe SCD Patients
HGB-205 SCD: Safety and Clinical Status in Severe SCD Patients Adverse events generally consistent with myeloablative conditioning No drug-product related non-hematologic AEs or SAEs No replication competent lentivirus (RCL) detected to date No evidence of insertional mutagenesis Patient 1204 One ep
Slide 34: SCD: Transfused Patients Have More Stable VCN
SCD: Transfused Patients Have More Stable VCN HGB-206 (Process 1) HGB-205 (Process 0) * Dotted lines represent transfused patients
Slide 35: SCD HbAT87Q Production Higher in Transfused Patients
SCD HbAT87Q Production Higher in Transfused Patients HGB-206 (Process 1) HGB-205 (Process 0) Data from transplant and other literature argue that as little as 3g/dL (~30%) of anti-sickling hemoglobin and gene marking as low as 20% could potentially achieve a disease-modifying effect * Dotted lines r
Slide 36: HGB-205 SCD: Levels of Anti-sickling Hemoglobin Above 30%
1204 1207 1208 50% 48% 20% 61% 15% 15% 39% 16% HbAT87Q HbF HbS HbA (transfused) HbA2 HGB-205 SCD: Levels of Anti-sickling Hemoglobin (HbAT87Q + HbF) Above 30%
Slide 37: Evolution of LentiGlobin in SCD – More To Come at ASH 2017
Evolution of LentiGlobin in SCD – More To Come at ASH 2017 HGB-206 Process 1 HGB-206 Updated Protocol HGB-206 (Apheresis) Low/Med Low Low No High Medium High Yes High High High Yes HGB-205 High Medium Medium Yes Transfusions (Pre-Treatment) Conditioning Total Cell Dose Transduction (VCN & % Transduc
Slide 38: Closing
Closing
Slide 39: Key Questions
Key Questions Transfusion-Dependent β-thalassemia (TDT): Northstar-2 and HGB-205 With our new manufacturing process in Northstar-2, are we able to consistently manufacture drug product (DP) with higher vector copy number (VCN) and proportion of transduced cells? How do the early results from Northst
Slide 40: Bringing & Valuing Hope
Bringing & Valuing Hope Go TRUE BLUE We Must Make Hope a Reality